Lind, Stuart E.
New England Journal of Medicine. 1986 Jan 30; 314(5): 312-315.
The development of monoclonal antibodies to treat cancer, and particularly the possibility of designing a set unique for each patient, has raised the specter of such experimental treatments someday being offered by for-profit companies to those who can afford to underwrite the costs of the research. Lind discusses some of the scientific, economic, and ethical issues raised by this kind of fee-for-service research. These include lack of patient protection by ethics committees, government regulation, or informed consent requirements; restriction of information and availability of treatment due to the developer's proprietary interests; conflict of interest for the researcher/physician; unequal access to new treatments; and possible depletion of family resources spent to purchase unproven therapies. (KIE abstract)
Biomedical Research; Body Parts and Fluids; Cancer; Conflict of Interest; Contracts; Consent; Drug Industry; Drugs; Economics; Ethics; Ethics Committees; Financial Support; Government; Government Regulation; Human Experimentation; Industry; Informed Consent; Investigators; Physicians; Property Rights; Property; Regulation; Research; Research Ethics; Research Ethics Committees; Research Subjects; Rights; Selection for Treatment; Selection of Subjects; Therapeutic Research;
Showing items related by title, author, creator and subject.
Lind, Stuart E. (1986-01-30)
Rutstein, David D.; Marshall, Gailen D.; Schrogie, John J. (1986-10-23)
Spiro, Howard M. (1988)